Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated at Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $58.00 price target on the biopharmaceutical company’s stock.

CLDX has been the topic of several other reports. Cantor Fitzgerald reaffirmed an overweight rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Guggenheim upped their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the company a buy rating in a research report on Tuesday, February 27th. HC Wainwright reaffirmed a buy rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Monday, June 3rd. Finally, Wolfe Research assumed coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They set an outperform rating and a $51.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Celldex Therapeutics has an average rating of Moderate Buy and an average price target of $62.17.

Celldex Therapeutics Stock Down 1.2 %

CLDX opened at $35.27 on Tuesday. The business has a fifty day moving average of $37.27 and a 200 day moving average of $39.03. Celldex Therapeutics has a 52-week low of $22.11 and a 52-week high of $53.18. The stock has a market cap of $2.32 billion, a P/E ratio of -12.38 and a beta of 1.47.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. Equities analysts anticipate that Celldex Therapeutics will post -2.32 EPS for the current fiscal year.

Insider Buying and Selling at Celldex Therapeutics

In other Celldex Therapeutics news, CFO Samuel Bates Martin sold 35,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.05, for a total transaction of $1,191,750.00. Following the sale, the chief financial officer now owns 25,128 shares in the company, valued at approximately $855,608.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, SVP Margo Heath-Chiozzi sold 38,719 shares of the company’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.07, for a total value of $1,319,156.33. Following the sale, the senior vice president now owns 7,094 shares in the company, valued at $241,692.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Samuel Bates Martin sold 35,000 shares of the company’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the completion of the sale, the chief financial officer now owns 25,128 shares in the company, valued at approximately $855,608.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 266,332 shares of company stock worth $9,155,821. 3.80% of the stock is currently owned by insiders.

Institutional Trading of Celldex Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in shares of Celldex Therapeutics in the first quarter worth about $824,000. Artal Group S.A. purchased a new position in Celldex Therapeutics during the first quarter worth approximately $10,618,000. California State Teachers Retirement System boosted its position in Celldex Therapeutics by 13.5% during the first quarter. California State Teachers Retirement System now owns 58,403 shares of the biopharmaceutical company’s stock worth $2,451,000 after purchasing an additional 6,929 shares in the last quarter. Bayesian Capital Management LP purchased a new position in Celldex Therapeutics during the first quarter worth approximately $470,000. Finally, Public Employees Retirement Association of Colorado purchased a new position in Celldex Therapeutics during the first quarter worth approximately $327,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.